Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Autoimmune Disorders

Free Subscription Articles published in Ann Neurol Retrieve available abstracts of 143 articles: HTML format

Single Articles

July 2021
1. HANDUNNETTHI L, Knezevic B, Kasela S, Burnham KL, et al
   Genomic insights into myasthenia gravis identify distinct immunological mechanisms in early and late onset disease.
   Ann Neurol. 2021 Jul 19. doi: 10.1002/ana.26169.
   PubMed     Abstract available
   
   
   
2. METZ I, Gavrilova RH, Weigand SD, Frischer JM, et al
   MRI Correlates of Multiple Sclerosis Immunopathological Patterns.
   Ann Neurol. 2021 Jul 7. doi: 10.1002/ana.26163.
   PubMed     Abstract available
   
   
   
3. GELIBTER S, Pisa M, Croese T, Finardi A, et al
   Spinal fluid myeloid microvesicles predict disease course in multiple sclerosis.
   Ann Neurol. 2021 Jul 3. doi: 10.1002/ana.26154.
   PubMed     Abstract available
   
   
   
4. HAUSER SL
   Curing Multiple Sclerosis: How to Know When We're There?
   Ann Neurol. 2021 Jul 2. doi: 10.1002/ana.26155.
   PubMed    
   
   
   June 2021
5. ALLEN CM, Ramsamy S, Tarr AW, Tighe PJ, et al
   Guillain-Barre syndrome variant occurring after SARS-CoV-2 vaccination.
   Ann Neurol. 2021 Jun 10. doi: 10.1002/ana.26144.
   PubMed     Abstract available
   
   
   
6. MARAMMATOM BV, Krishnan P, Paul R, Padmanabhan S, et al
   Guillain-Barre syndrome following ChAdOx1-S/nCoV-19 vaccine.
   Ann Neurol. 2021 Jun 10. doi: 10.1002/ana.26143.
   PubMed     Abstract available
   
   
   May 2021
7. OECHTERING J, Schaedelin S, Benkert P, Muller S, et al
   Intrathecal Immunoglobulin M synthesis is an independent biomarker for higher disease activity and severity in multiple sclerosis.
   Ann Neurol. 2021 May 31. doi: 10.1002/ana.26137.
   PubMed     Abstract available
   
   
   
8. BEUKER C, Wankner MC, Thomas C, Strecker JK, et al
   Characterization of extracranial giant cell arteritis with intracranial involvement and its rapidly progressive subtype.
   Ann Neurol. 2021 May 16. doi: 10.1002/ana.26101.
   PubMed    
   
   
   
9. LANDA J, Guasp M, Miguez-Cabello F, Guimaraes J, et al
   Encephalitis with autoantibodies against the glutamate kainate receptors GluK2.
   Ann Neurol. 2021 May 5. doi: 10.1002/ana.26098.
   PubMed     Abstract available
   
   
   
10. AKTAS O, Smith MA, Rees WA, Bennett JL, et al
    Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.
    Ann Neurol. 2021;89:895-910.
    PubMed     Abstract available
    
    
    April 2021
11. IZUKA S, Kobayashi T, Takahashi Y
    Tongue tremor in systemic lupus erythematosus.
    Ann Neurol. 2021 Apr 21. doi: 10.1002/ana.26088.
    PubMed    
    
    
    
12. COX LM, Maghzi AH, Liu S, Tankou SK, et al
    The Gut Microbiome in Progressive Multiple Sclerosis.
    Ann Neurol. 2021 Apr 19. doi: 10.1002/ana.26084.
    PubMed     Abstract available
    
    
    
13. MIRO O, Porta-Etessam J, Gonzalez Del Castillo J
    Reply to: "COVID-19 and the Risk of GBS".
    Ann Neurol. 2021;89:846-847.
    PubMed    
    
    
    
14. PETZOLD A
    Reply to "Peripapillary Hyper-Reflective Ovoid Masslike Structures in Astronauts".
    Ann Neurol. 2021;89:849-850.
    PubMed    
    
    
    
15. WOSTYN P, Gibson CR, Mader TH
    Peripapillary Hyper-Reflective Ovoid Mass-Like Structures in Astronauts.
    Ann Neurol. 2021;89:849.
    PubMed    
    
    
    
16. LUCHICCHI A, Hart B, Frigerio I, van Dam AM, et al
    Axon-Myelin Unit Blistering as Early Event in MS Normal Appearing White Matter.
    Ann Neurol. 2021;89:711-725.
    PubMed     Abstract available
    
    
    March 2021
17. VANDEBERGH M, Andlauer TFM, Zhou Y, Mallants K, et al
    Genetic variation in WNT9B increases relapse hazard in multiple sclerosis.
    Ann Neurol. 2021 Mar 11. doi: 10.1002/ana.26061.
    PubMed     Abstract available
    
    
    
18. NOURBAKHSH B, Cordano C, Asteggiano C, Ruprecht K, et al
    Multiple Sclerosis Is Rare in Epstein-Barr Virus-Seronegative Children with Central Nervous System Inflammatory Demyelination.
    Ann Neurol. 2021 Mar 11. doi: 10.1002/ana.26062.
    PubMed     Abstract available
    
    
    February 2021
19. DE MEO E, Bonacchi R, Moiola L, Colombo B, et al
    Early predictors of 9-year disability in pediatric multiple sclerosis.
    Ann Neurol. 2021 Feb 17. doi: 10.1002/ana.26052.
    PubMed     Abstract available
    
    
    
20. DUBEY D, Kryzer T, Guo Y, Clarkson B, et al
    LUZP4 autoantibody: A novel germ cell tumor and paraneoplastic biomarker.
    Ann Neurol. 2021 Feb 14. doi: 10.1002/ana.26050.
    PubMed     Abstract available
    
    
    January 2021
21. SORMANI MP, De Rossi N, Schiavetti I, Carmisciano L, et al
    Disease modifying therapies and Covid-19 severity in Multiple Sclerosis.
    Ann Neurol. 2021 Jan 21. doi: 10.1002/ana.26028.
    PubMed     Abstract available
    
    
    
22. KOAY S, Vichayanrat E, Bremner F, Panicker JN, et al
    Multi-modal Biomarkers Quantify Recovery in Autoimmune Autonomic Ganglionopathy.
    Ann Neurol. 2021 Jan 13. doi: 10.1002/ana.26018.
    PubMed     Abstract available
    
    
    
23. DE BRUIJN MAAM, Bastiaansen AEM, Mojzisova H, van Sonderen A, et al
    The Antibodies Contributing to focal Epilepsy Signs and symptoms (ACES) score.
    Ann Neurol. 2021 Jan 11. doi: 10.1002/ana.26013.
    PubMed     Abstract available
    
    
    
24. LEE ST, Lee BJ, Bae JY, Kim YS, et al
    CaV alpha2delta Autoimmune Encephalitis: A Novel Antibody and its Characteristics.
    Ann Neurol. 2021 Jan 7. doi: 10.1002/ana.26017.
    PubMed     Abstract available
    
    
    
25. RINALDI S
    Coronavirus Disease 2019 and the Risk of Guillain-Barre Syndrome.
    Ann Neurol. 2021 Jan 4. doi: 10.1002/ana.26011.
    PubMed    
    
    
    December 2020
26. FRAGIEL M, Miro O, Llorens P, Jimenez S, et al
    Incidence, clinical characteristics, risk factors and outcomes of Guillain-Barre syndrome in patients with Covid-19.
    Ann Neurol. 2020 Dec 9. doi: 10.1002/ana.25987.
    PubMed     Abstract available
    
    
    November 2020
27. THAM M, Frischer JM, Weigand SD, Fitz-Gibbon PD, et al
    Iron heterogeneity in early active multiple sclerosis lesions.
    Ann Neurol. 2020 Nov 27. doi: 10.1002/ana.25974.
    PubMed     Abstract available
    
    
    
28. FADDA G, Banwell B, Waters P, Marrie RA, et al
    Silent new brain MRI lesions in children with MOG-antibody associated disease.
    Ann Neurol. 2020 Nov 19. doi: 10.1002/ana.25957.
    PubMed     Abstract available
    
    
    October 2020
29. SOTIRCHOS ES, Calabresi PA, Saidha S
    Reply to "Retinal INL thickness in multiple sclerosis: a mere marker of neurodegeneration?"
    Ann Neurol. 2020 Oct 17. doi: 10.1002/ana.25936.
    PubMed    
    
    
    
30. CORDANO C, Yiu HH, Oertel FC, Gelfand JM, et al
    Retinal INL thickness in multiple sclerosis: a mere marker of neurodegeneration?
    Ann Neurol. 2020 Oct 17. doi: 10.1002/ana.25933.
    PubMed    
    
    
    
31. COMI G, Bar-Or A, Lassmann H, Uccelli A, et al
    The role of B cells in Multiple Sclerosis and related disorders.
    Ann Neurol. 2020 Oct 9. doi: 10.1002/ana.25927.
    PubMed     Abstract available
    
    
    September 2020
32. VARLEY JA, Andersson M, Grant E, Berretta A, et al
    Absence of neuronal autoantibodies in neuropsychiatric systemic lupus erythematosus.
    Ann Neurol. 2020 Sep 19. doi: 10.1002/ana.25908.
    PubMed     Abstract available
    
    
    
33. CIOTTI JR, Grebenciucova E, Moss BP, Newsome SD, et al
    Multiple Sclerosis Disease-Modifying Therapies in the COVID-19 Era.
    Ann Neurol. 2020 Sep 19. doi: 10.1002/ana.25907.
    PubMed    
    
    
    
34. CARCELES-CORDON M, Mannara F, Aguilar E, Castellanos A, et al
    NMDAR Antibodies Alter Dopamine Receptors and Cause Psychotic Behavior in Mice.
    Ann Neurol. 2020;88:603-613.
    PubMed     Abstract available
    
    
    August 2020
35. PALMA JA, Gupta A, Sierra S, Gomes I, et al
    Autoantibodies blocking M3 muscarinic receptors cause postganglionic cholinergic dysautonomia.
    Ann Neurol. 2020 Aug 24. doi: 10.1002/ana.25882.
    PubMed     Abstract available
    
    
    
36. MAGGI P, Sati P, Nair G, Cortese ICM, et al
    PARAMAGNETIC RIM LESIONS ARE SPECIFIC TO MULTIPLE SCLEROSIS: AN INTERNATIONAL MULTICENTER 3T MRI STUDY.
    Ann Neurol. 2020 Aug 15. doi: 10.1002/ana.25877.
    PubMed     Abstract available
    
    
    
37. LANDA J, Gaig C, Planaguma J, Saiz A, et al
    Effects of IgLON5 antibodies on neuronal cytoskeleton: a link between autoimmunity and neurodegeneration.
    Ann Neurol. 2020 Aug 2. doi: 10.1002/ana.25857.
    PubMed     Abstract available
    
    
    
38. PETZOLD A, Coric D, Balk LJ, Hamann S, et al
    Longitudinal Development of Peripapillary Hyper-Reflective Ovoid Masslike Structures Suggests a Novel Pathological Pathway in Multiple Sclerosis.
    Ann Neurol. 2020;88:309-319.
    PubMed     Abstract available
    
    
    July 2020
39. KHOURY SJ
    Progressive Multiple Sclerosis.
    Ann Neurol. 2020 Jul 6. doi: 10.1002/ana.25802.
    PubMed    
    
    
    
40. KORALNIK IJ, Tyler KL
    COVID-19: A Global Threat to the Nervous System.
    Ann Neurol. 2020;88:1-11.
    PubMed     Abstract available
    
    
    
41. KRYSKO KM, Graves JS, Rensel M, Weinstock-Guttman B, et al
    Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis.
    Ann Neurol. 2020;88:42-55.
    PubMed     Abstract available
    
    
    June 2020
42. PETROVA N, Nutma E, Carassiti D, Newman J, et al
    Synaptic loss in the multiple sclerosis spinal cord.
    Ann Neurol. 2020 Jun 30. doi: 10.1002/ana.25835.
    PubMed     Abstract available
    
    
    
43. RAUSCHENBERGER V, Wardenburg NV, Schaefer N, Ogino K, et al
    GlyR autoantibodies impair receptor function and induce motor dysfunction.
    Ann Neurol. 2020 Jun 26. doi: 10.1002/ana.25832.
    PubMed     Abstract available
    
    
    
44. FILIPPI M, Preziosa P, Langdon D, Lassmann H, et al
    Identifying Progression In Multiple Sclerosis: New Perspectives.
    Ann Neurol. 2020 Jun 7. doi: 10.1002/ana.25808.
    PubMed     Abstract available
    
    
    
45. LEBRUN-FRENAY C, Kantarci O, Siva A, Sormani MP, et al
    Radiologically Isolated Syndrome: 10-Year Risk Estimate of a Clinical Event.
    Ann Neurol. 2020 Jun 4. doi: 10.1002/ana.25799.
    PubMed     Abstract available
    
    
    May 2020
46. MAGLIOZZI R, Scalfari A, Pisani AI, Ziccardi S, et al
    The CSF profile linked to cortical damage predicts Multiple Sclerosis activity.
    Ann Neurol. 2020 May 17. doi: 10.1002/ana.25786.
    PubMed     Abstract available
    
    
    
47. AMOR S, Baker D, Khoury SJ, Schmierer K, et al
    SARS-CoV-2 and Multiple Sclerosis: Not all immune depleting DMTs are equal or bad.
    Ann Neurol. 2020 May 8. doi: 10.1002/ana.25770.
    PubMed     Abstract available
    
    
    
48. MATIAS-GUIU JA, Cabrera-Martin MN, Pytel V, Montero P, et al
    Amyloid PET in Multiple Sclerosis: between amyloid deposition and myelin damage.
    Ann Neurol. 2020 May 1. doi: 10.1002/ana.25759.
    PubMed    
    
    
    
49. LEE ST, Lim JA, Chu K, Lee SK, et al
    Reply to "Grading the severity of autoimmune encephalitis: When to evaluate?"
    Ann Neurol. 2020 May 1. doi: 10.1002/ana.25760.
    PubMed    
    
    
    
50. CAI MT, Zheng Y, Zhang YX
    Grading the severity of autoimmune encephalitis: When to evaluate?
    Ann Neurol. 2020 May 1. doi: 10.1002/ana.25761.
    PubMed    
    
    
    April 2020
51. ZEYDAN B, Kantarci K, Kantarci OH
    Reply to "Amyloid PET in Multiple Sclerosis: between amyloid deposition and myelin damage".
    Ann Neurol. 2020 Apr 30. doi: 10.1002/ana.25758.
    PubMed    
    
    
    
52. BARTELS F, Krohn S, Nikolaus M, Johannsen J, et al
    Clinical and MRI Outcome Predictors in Pediatric Anti-NMDA Receptor Encephalitis.
    Ann Neurol. 2020 Apr 21. doi: 10.1002/ana.25754.
    PubMed     Abstract available
    
    
    
53. DESAI RA, Davies AL, Del Rossi N, Tachrount M, et al
    Nimodipine reduces dysfunction and demyelination in models of multiple sclerosis.
    Ann Neurol. 2020 Apr 15. doi: 10.1002/ana.25749.
    PubMed     Abstract available
    
    
    
54. MAHAJAN KR, Nakamura K, Cohen JA, Trapp BD, et al
    Intrinsic and extrinsic mechanisms of thalamic pathology in multiple sclerosis.
    Ann Neurol. 2020 Apr 14. doi: 10.1002/ana.25743.
    PubMed     Abstract available
    
    
    
55. COLE JH, Raffel J, Friede T, Eshaghi A, et al
    Longitudinal assessment of multiple sclerosis with the brain-age paradigm.
    Ann Neurol. 2020 Apr 14. doi: 10.1002/ana.25746.
    PubMed     Abstract available
    
    
    
56. SOTIRCHOS ES, Caldito NG, Filippatou A, Fitzgerald KC, et al
    Progressive multiple sclerosis is associated with faster and specific retinal layer atrophy.
    Ann Neurol. 2020 Apr 13. doi: 10.1002/ana.25738.
    PubMed     Abstract available
    
    
    March 2020
57. PITSCH J, Kamalizade D, Braun A, Kuehn JC, et al
    Drebrin autoantibodies in patients with seizures and suspected encephalitis.
    Ann Neurol. 2020 Mar 20. doi: 10.1002/ana.25720.
    PubMed     Abstract available
    
    
    
58. DE MOL CL, Jansen PR, Muetzel RL, Knol MJ, et al
    Polygenic multiple sclerosis risk and population-based childhood brain imaging.
    Ann Neurol. 2020 Mar 12. doi: 10.1002/ana.25717.
    PubMed     Abstract available
    
    
    
59. RICHIE M, Pleasure S, Hurley J, Goss A, et al
    ANA Investigates: Pioneering Unbiased Diagnostics.
    Ann Neurol. 2020;87:327-328.
    PubMed    
    
    
    February 2020
60. OUELLETTE R, Mangeat G, Polyak I, Warntjes M, et al
    Validation of rapid magnetic resonance myelin imaging in multiple sclerosis.
    Ann Neurol. 2020 Feb 14. doi: 10.1002/ana.25705.
    PubMed     Abstract available
    
    
    
61. ALPING P, Askling J, Burman J, Fink K, et al
    Cancer Risk for Fingolimod, Natalizumab, and Rituximab in MS Patients.
    Ann Neurol. 2020 Feb 13. doi: 10.1002/ana.25701.
    PubMed     Abstract available
    
    
    
62. MATUTE C, Palma A, Serrano-Regal MP, Maudes E, et al
    NMDA receptor antibodies in autoimmune encephalopathy alter oligodendrocyte function.
    Ann Neurol. 2020 Feb 12. doi: 10.1002/ana.25699.
    PubMed     Abstract available
    
    
    
63. DALMAU J
    Pregnancy, N-Methyl-D-Aspartate Receptor Antibodies, and Neuropsychiatric Diseases.
    Ann Neurol. 2020;87:324-325.
    PubMed    
    
    
    
64. JUREK B, Chayka M, Kreye J, Koelch M, et al
    Reply to "Pregnancy, N-Methyl-D-Aspartate Receptor Antibodies, and Neuropsychiatric Diseases".
    Ann Neurol. 2020;87:325-326.
    PubMed    
    
    
    January 2020
65. OLDONI E, Smets I, Mallants K, Vandebergh M, et al
    CHIT1 at diagnosis reflects long-term multiple sclerosis disease activity.
    Ann Neurol. 2020 Jan 29. doi: 10.1002/ana.25691.
    PubMed     Abstract available
    
    
    
66. DOBSON R, Jitlal M, Marshall CR, Noyce AJ, et al
    Ethnic and socioeconomic associations with multiple sclerosis risk.
    Ann Neurol. 2020 Jan 23. doi: 10.1002/ana.25688.
    PubMed     Abstract available
    
    
    
67. ZEYDAN B, Lowe VJ, Reichard RR, Przybelski SA, et al
    Imaging Biomarkers of Alzheimer's Disease in Multiple Sclerosis.
    Ann Neurol. 2020 Jan 22. doi: 10.1002/ana.25684.
    PubMed     Abstract available
    
    
    
68. KORNAU HC, Kreye J, Stumpf A, Fukata Y, et al
    Human CSF monoclonal LGI1 autoantibodies increase neuronal excitability.
    Ann Neurol. 2020 Jan 3. doi: 10.1002/ana.25666.
    PubMed     Abstract available
    
    
    November 2019
69. DUBEY D, Britton J, McKeon A, Gadoth A, et al
    Randomized Placebo Controlled Trial of IVIG in autoimmune LGI1/CASPR2 epilepsy.
    Ann Neurol. 2019 Nov 28. doi: 10.1002/ana.25655.
    PubMed     Abstract available
    
    
    
70. CHUNG KK, Altmann D, Barkhof F, Miszkiel K, et al
    A thirty year clinical and MRI observational study of multiple sclerosis and clinically isolated syndromes.
    Ann Neurol. 2019 Nov 6. doi: 10.1002/ana.25637.
    PubMed     Abstract available
    
    
    
71. PROBSTEL AK, Zamvil SS
    Do maternal anti-N-methyl-D-aspartate receptor antibodies promote development of neuropsychiatric disease in children?
    Ann Neurol. 2019;86:653-655.
    PubMed    
    
    
    September 2019
72. KRYSKO KM, Henry RG, Cree BAC, Lin J, et al
    Telomere length is associated with disability progression in multiple sclerosis.
    Ann Neurol. 2019 Sep 4. doi: 10.1002/ana.25592.
    PubMed     Abstract available
    
    
    August 2019
73. MOCCIA M, Prados F, Filippi M, Rocca MA, et al
    Longitudinal spinal cord atrophy in multiple sclerosis using the generalised boundary shift integral.
    Ann Neurol. 2019 Aug 6. doi: 10.1002/ana.25571.
    PubMed     Abstract available
    
    
    
74. LOONSTRA FC, Verberk IMW, Wijburg MT, Wattjes MP, et al
    Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy.
    Ann Neurol. 2019;86:322-324.
    PubMed    
    
    
    
75. DALLA COSTA G, Martinelli V, Furlan R, Comi G, et al
    Reply to "Serum Neurofilaments as Candidate Biomarkers of Natalizumab Progressive Multifocal Leukoencephalopathy".
    Ann Neurol. 2019;86:324.
    PubMed    
    
    
    July 2019
76. JUREK B, Chayka M, Kreye J, Lang K, et al
    Human gestational NMDAR autoantibodies impair neonatal murine brain function.
    Ann Neurol. 2019 Jul 20. doi: 10.1002/ana.25552.
    PubMed     Abstract available
    
    
    June 2019
77. GIL-PEROTIN S, Alcala C, Perez-Miralles FC, Casanova B, et al
    Silent progression or bout-onset progressive multiple sclerosis?
    Ann Neurol. 2019 Jun 28. doi: 10.1002/ana.25537.
    PubMed    
    
    
    
78. CREE BAC, Hauser SL
    Reply to "Silent progression or bout-onset progressive multiple sclerosis?"
    Ann Neurol. 2019 Jun 28. doi: 10.1002/ana.25536.
    PubMed    
    
    
    
79. MUNGER KL, Hongell K, Cortese M, Aivo J, et al
    Epstein-Barr virus and multiple sclerosis risk in the Finnish Maternity Cohort.
    Ann Neurol. 2019 Jun 21. doi: 10.1002/ana.25532.
    PubMed     Abstract available
    
    
    May 2019
80. VAN LANGELAAR J, Rijvers L, Janssen M, Wierenga-Wolf AF, et al
    Induction of brain-infiltrating T-bet-expressing B cells in multiple sclerosis.
    Ann Neurol. 2019 May 28. doi: 10.1002/ana.25508.
    PubMed     Abstract available
    
    
    
81. LIM JA, Lee ST, Chu K, Lee SK, et al
    Reply to "Grading the severity of autoimmune encephalitis: advances and pitfalls".
    Ann Neurol. 2019 May 2. doi: 10.1002/ana.25497.
    PubMed    
    
    
    
82. SPAGNI G, Iorio R
    Grading the severity of autoimmune encephalitis: advances and pitfalls.
    Ann Neurol. 2019 May 2. doi: 10.1002/ana.25496.
    PubMed    
    
    
    
83. NOLAN-KENNEY RC, Liu M, Akhand O, Calabresi PA, et al
    Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study.
    Ann Neurol. 2019;85:618-629.
    PubMed     Abstract available
    
    
    
84. WENKE NK, Kreye J, Andrzejak E, van Casteren A, et al
    N-methyl-D-aspartate receptor dysfunction by unmutated human antibodies against the NR1 subunit.
    Ann Neurol. 2019;85:771-776.
    PubMed     Abstract available
    
    
    March 2019
85. AKTAS O, Hartung HP
    CSI: Multiple sclerosis. Tracing optic nerve involvement by standardized optical coherence tomography.
    Ann Neurol. 2019 Mar 22. doi: 10.1002/ana.25471.
    PubMed    
    
    
    
86. CREE BAC, Hollenbach JA, Bove R, Kirkish G, et al
    Silent Progression in Disease Activity-Free Relapsing Multiple Sclerosis.
    Ann Neurol. 2019 Mar 9. doi: 10.1002/ana.25463.
    PubMed     Abstract available
    
    
    
87. THALER FS, Thaller AL, Biljecki M, Schuh E, et al
    Abundant glutamic acid decarboxylase (GAD)-reactive B cells in gad-antibody-associated neurological disorders.
    Ann Neurol. 2019;85:448-454.
    PubMed     Abstract available
    
    
    February 2019
88. DALLA COSTA G, Martinelli V, Moiola L, Sangalli F, et al
    Serum neurofilaments increase at PML onset in natalizumab-treated MS patients.
    Ann Neurol. 2019 Feb 13. doi: 10.1002/ana.25437.
    PubMed     Abstract available
    
    
    
89. FADDA G, Brown RA, Magliozzi R, Aubert-Broche B, et al
    A surface-in gradient of thalamic damage evolves in pediatric multiple sclerosis.
    Ann Neurol. 2019 Feb 4. doi: 10.1002/ana.25429.
    PubMed     Abstract available
    
    
    January 2019
90. LIM JA, Lee ST, Moon J, Jun JS, et al
    Development of the Clinical Assessment Scale in Autoimmune Encephalitis (CASE).
    Ann Neurol. 2019 Jan 24. doi: 10.1002/ana.25421.
    PubMed     Abstract available
    
    
    
91. BAERT L, Benkhoucha M, Popa N, Ahmed MC, et al
    APRIL-mediated anti-inflammatory response of astrocytes in multiple sclerosis.
    Ann Neurol. 2019 Jan 11. doi: 10.1002/ana.25415.
    PubMed     Abstract available
    
    
    
92. CACCIAGUERRA L, Meani A, Mesaros S, Radaelli M, et al
    Brain and cord imaging features in neuromyelitis optica spectrum disorders.
    Ann Neurol. 2019 Jan 11. doi: 10.1002/ana.25411.
    PubMed     Abstract available
    
    
    October 2018
93. BEVAN RJ, Evans R, Griffiths L, Watkins LM, et al
    MENINGEAL INFLAMMATION AND CORTICAL DEMYELINATION IN ACUTE MULTIPLE SCLEROSIS.
    Ann Neurol. 2018 Oct 25. doi: 10.1002/ana.25365.
    PubMed     Abstract available
    
    
    September 2018
94. HE D, Zhang H, Xiao J, Zhang X, et al
    Molecular and clinical relationship between live-attenuated Japanese encephalitis vaccination and childhood onset myasthenia gravis.
    Ann Neurol. 2018;84:386-400.
    PubMed     Abstract available
    
    
    August 2018
95. WOLINSKY JS, Montalban X, Hauser SL, Giovannoni G, et al
    Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial.
    Ann Neurol. 2018 Aug 29. doi: 10.1002/ana.25313.
    PubMed     Abstract available
    
    
    
96. SEBASTIAN LOPEZ-CHIRIBOGA A, Klein C, Zekeridou A, McKeon A, et al
    LGI1 and CASPR2 Neurological Autoimmunity in Children.
    Ann Neurol. 2018 Aug 3. doi: 10.1002/ana.25310.
    PubMed     Abstract available
    
    
    July 2018
97. FUJII T, Yamasaki R, Iinuma K, Tsuchimoto D, et al
    A novel autoantibody against plexin D1 in patients with neuropathic pain.
    Ann Neurol. 2018 Jul 16. doi: 10.1002/ana.25279.
    PubMed     Abstract available
    
    
    June 2018
98. JIA X, Madireddy L, Caillier S, Santaniello A, et al
    Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis.
    Ann Neurol. 2018 Jun 16. doi: 10.1002/ana.25263.
    PubMed     Abstract available
    
    
    May 2018
99. DISANTO G, Zecca C, MacLachlan S, Sacco R, et al
    Prodromal symptoms of multiple sclerosis in primary care.
    Ann Neurol. 2018 May 8. doi: 10.1002/ana.25247.
    PubMed     Abstract available
    
    
    April 2018
100. TANKOU SK, Regev K, Healy BC, Tjon E, et al
     A probiotic modulates the microbiome and immunity in multiple sclerosis.
     Ann Neurol. 2018 Apr 20. doi: 10.1002/ana.25244.
     PubMed     Abstract available
     
     
     
101. VOGRIG A, Brigo F, Valente M, Gigli GL, et al
     Epidemiology of autoimmune versus infectious encephalitis.
     Ann Neurol. 2018 Apr 10. doi: 10.1002/ana.25229.
     PubMed    
     
     
     
102. DUBEY D, Pittock SJ, Toledano M, Flanagan EP, et al
     Reply to "Epidemiology of autoimmune versus infectious encephalitis".
     Ann Neurol. 2018 Apr 10. doi: 10.1002/ana.25230.
     PubMed    
     
     
     March 2018
103. CRAMER SP, Simonsen HJ, Varatharaj A, Galea I, et al
     Permeability of the blood-brain barrier predicts no evidence of disease activity at two years after natalizumab or fingolimod treatment in relapsing-remitting multiple sclerosis.
     Ann Neurol. 2018 Mar 31. doi: 10.1002/ana.25219.
     PubMed     Abstract available
     
     
     
104. ANTEL J
     The reality of "ghosts" in authorship of clinical trials in multiple sclerosis.
     Ann Neurol. 2018 Mar 13. doi: 10.1002/ana.25199.
     PubMed    
     
     
     
105. COLES A
     Authorship of phase 3 trials in multiple sclerosis.
     Ann Neurol. 2018 Mar 8. doi: 10.1002/ana.25203.
     PubMed    
     
     
     
106. MAGLIOZZI R, Howell OW, Nicholas R, Cruciani C, et al
     Inflammatory intrathecal profiles and cortical damage in multiple sclerosis.
     Ann Neurol. 2018 Mar 8. doi: 10.1002/ana.25197.
     PubMed     Abstract available
     
     
     February 2018
107. JENDE JME, Groener JB, Oikonomou D, Heiland S, et al
     Diabetic neuropathy differs between type 1 and type 2 diabetes Insights from magnetic resonance neurography.
     Ann Neurol. 2018 Feb 14. doi: 10.1002/ana.25182.
     PubMed     Abstract available
     
     
     
108. BECK ES, Reich DS
     Brain atrophy in multiple sclerosis: How deep must we go?
     Ann Neurol. 2018;83:208-209.
     PubMed    
     
     
     
109. MAGGI P, Absinta M, Grammatico M, Vuolo L, et al
     Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies.
     Ann Neurol. 2018;83:283-294.
     PubMed     Abstract available
     
     
     January 2018
110. ESHAGHI A, Prados F, Brownlee W, Altmann DR, et al
     Deep grey matter volume loss drives disability worsening in multiple sclerosis.
     Ann Neurol. 2018 Jan 13. doi: 10.1002/ana.25145.
     PubMed     Abstract available
     
     
     
111. AZEVEDO CJ, Cen SY, Khadka S, Liu S, et al
     Thalamic Atrophy in MS: An MRI Marker of Neurodegeneration Throughout Disease.
     Ann Neurol. 2018 Jan 12. doi: 10.1002/ana.25150.
     PubMed     Abstract available
     
     
     
112. DUBEY D, Pittock SJ, Kelly CR, McKeon A, et al
     Autoimmune Encephalitis Epidemiology and a comparison to Infectious Encephalitis.
     Ann Neurol. 2018 Jan 2. doi: 10.1002/ana.25131.
     PubMed     Abstract available
     
     
     December 2017
113. GILES DA, Washnock-Schmid JM, Duncker PC, Dahlawi S, et al
     Myeloid cell plasticity in the evolution of central nervous system autoimmunity.
     Ann Neurol. 2017 Dec 28. doi: 10.1002/ana.25128.
     PubMed     Abstract available
     
     
     
114. GREENFIELD AL, Hauser SL
     B Cell Therapy for Multiple Sclerosis: Entering an Era.
     Ann Neurol. 2017 Dec 15. doi: 10.1002/ana.25119.
     PubMed     Abstract available
     
     
     
115. PATTERSON KR, Dalmau J, Lancaster E
     Mechanisms of Caspr2 antibodies in autoimmune encephalitis and neuromyotonia.
     Ann Neurol. 2017 Dec 15. doi: 10.1002/ana.25120.
     PubMed     Abstract available
     
     
     November 2017
116. KANAI T, Uzawa A, Sato Y, Suzuki S, et al
     A clinical predictive score for postoperative myasthenic crisis.
     Ann Neurol. 2017;82:841-849.
     PubMed     Abstract available
     
     
     October 2017
117. BARBOUR C, Kosa P, Komori M, Tanigawa M, et al
     Molecular-based diagnosis of Multiple Sclerosis and its progressive stage.
     Ann Neurol. 2017 Oct 23. doi: 10.1002/ana.25083.
     PubMed     Abstract available
     
     
     
118. AZODI S, Nair G, Enose-Akahata Y, Charlip E, et al
     Imaging Spinal Cord Atrophy in Progressive Myelopathies: HTLV-I Associated Neurologic Disease (HAM/TSP) and Multiple Sclerosis (MS).
     Ann Neurol. 2017 Oct 10. doi: 10.1002/ana.25072.
     PubMed     Abstract available
     
     
     
119. JENDE JME, Hauck GH, Diem R, Weiler M, et al
     Peripheral nerve involvement in multiple sclerosis Demonstration by magnetic resonance neurography.
     Ann Neurol. 2017 Oct 10. doi: 10.1002/ana.25068.
     PubMed     Abstract available
     
     
     
120. MAINERO C, Louapre C
     Unravelling cortical pathology in multiple sclerosis using the T1-/T2-weighted ratio?
     Ann Neurol. 2017 Oct 4. doi: 10.1002/ana.25063.
     PubMed    
     
     
     
121. WIJNANDS JMA, Tremlett H
     Concussion may not cause multiple sclerosis.
     Ann Neurol. 2017 Oct 4. doi: 10.1002/ana.25061.
     PubMed    
     
     
     
122. MONTGOMERY S, Hiyoshi A, Burkill S, Alfredsson L, et al
     Reply to: Concussion may not cause multiple sclerosis.
     Ann Neurol. 2017 Oct 4. doi: 10.1002/ana.25062.
     PubMed    
     
     
     September 2017
123. FITZGERALD KC, Munger KL, Ascherio A
     Reply to "Stratified analyses are necessary to verify the influence of salt intake in multiple sclerosis".
     Ann Neurol. 2017 Sep 29. doi: 10.1002/ana.25055.
     PubMed    
     
     
     
124. ZAHEDNASAB H, Harirchian MH, Karampoor S, Keyvani H, et al
     MMP-9 as a biomarker of PML development in MS patients receiving Natalizumab.
     Ann Neurol. 2017 Sep 4. doi: 10.1002/ana.25037.
     PubMed    
     
     
     
125. FISSOLO N, Pignolet B, Brassat D, Comabella M, et al
     Reply: MMP-9 as a biomarker of PML development in MS patients receiving Natalizumab.
     Ann Neurol. 2017 Sep 4. doi: 10.1002/ana.25039.
     PubMed    
     
     
     
126. MONTGOMERY S, Hiyoshi A, Burkill S, Alfredsson L, et al
     Concussion in adolescence and risk of multiple sclerosis.
     Ann Neurol. 2017 Sep 4. doi: 10.1002/ana.25036.
     PubMed     Abstract available
     
     
     August 2017
127. NAKAMURA K, Chen JT, Ontaneda D, Fox RJ, et al
     T1-/T2-weighted ratio differs in demyelinated cortex of multiple sclerosis.
     Ann Neurol. 2017 Aug 18. doi: 10.1002/ana.25019.
     PubMed     Abstract available
     
     
     
128. RIGHART R, Biberacher V, Jonkman LE, Klaver R, et al
     Cortical pathology in MS detected by the T1/T2-weighted ratio from routine MRI.
     Ann Neurol. 2017 Aug 18. doi: 10.1002/ana.25020.
     PubMed     Abstract available
     
     
     
129. DALAKAS MC, Rakocevic G, Dambrosia JM, Alexopoulos H, et al
     A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome.
     Ann Neurol. 2017;82:271-277.
     PubMed     Abstract available
     
     
     July 2017
130. YATES RL, Esiri MM, Palace J, Jacobs B, et al
     Fibrin(ogen) and neurodegeneration in the progressive multiple sclerosis cortex.
     Ann Neurol. 2017 Jul 18. doi: 10.1002/ana.24997.
     PubMed     Abstract available
     
     
     
131. FISSOLO N, Pignolet B, Matute-Blanch C, Trivino JC, et al
     MMP9 is decreased in natalizumab-treated MS patients at risk for PML.
     Ann Neurol. 2017 Jul 6. doi: 10.1002/ana.24987.
     PubMed     Abstract available
     
     
     May 2017
132. FITZGERALD KC, Munger KL, Hartung HP, Freedman MS, et al
     Sodium intake and multiple sclerosis activity and progression in BENEFIT.
     Ann Neurol. 2017 May 26. doi: 10.1002/ana.24965.
     PubMed     Abstract available
     
     
     
133. DISANTO G, Barro C, Benkert P, Naegelin Y, et al
     Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
     Ann Neurol. 2017 May 16. doi: 10.1002/ana.24954.
     PubMed     Abstract available
     
     
     
134. CUI QL, Khan D, Rone M, Rao V, et al
     Sublethal oligodendrocyte injury: A reversible condition in multiple sclerosis?
     Ann Neurol. 2017 May 3. doi: 10.1002/ana.24944.
     PubMed     Abstract available
     
     
     
135. IAFFALDANO P, Simone M, Lucisano G, Ghezzi A, et al
     Prognostic indicators in pediatric clinically isolated syndrome.
     Ann Neurol. 2017;81:729-739.
     PubMed     Abstract available
     
     
     April 2017
136. ANDRODIAS G, Bernard E, Biotti D, Collongues N, et al
     Multiple sclerosis broke my heart.
     Ann Neurol. 2017 Apr 24. doi: 10.1002/ana.24935.
     PubMed     Abstract available
     
     
     
137. SELMAJ I, Cichalewska M, Namiecinska M, Galazka G, et al
     Global Exosome Transcriptome Profiling Reveals Biomarkers for Multiple Sclerosis.
     Ann Neurol. 2017 Apr 15. doi: 10.1002/ana.24931.
     PubMed     Abstract available
     
     
     March 2017
138. TAWARA N, Yamashita S, Zhang X, Korogi M, et al
     Pathomechanisms of anti-cN1A autoantibodies in sporadic inclusion body myositis.
     Ann Neurol. 2017 Mar 20. doi: 10.1002/ana.24919.
     PubMed     Abstract available
     
     
     
139. TREMLETT H, Bauer KC, Appel-Cresswell S, Finlay BB, et al
     The gut microbiome in human neurological disease: A review.
     Ann Neurol. 2017;81:369-382.
     PubMed     Abstract available
     
     
     February 2017
140. KIM TJ, Lee ST, Moon J, Sunwoo JS, et al
     Anti-LGI1 encephalitis is associated with unique HLA subtypes.
     Ann Neurol. 2017;81:183-192.
     PubMed     Abstract available
     
     
     December 2016
141. HERRANZ E, Hooker JM, Izquierdo-Garcia D, Loggia ML, et al
     11 C-PBR28 increase in multiple sclerosis reflects neuroinflammation.
     Ann Neurol. 2016 Dec 29. doi: 10.1002/ana.24865.
     PubMed    
     
     
     
142. RAFFEL J, Sridharan S, Nicholas R
     [11 C]PBR-28 PET in multiple sclerosis: Neuroinflammation or otherwise?
     Ann Neurol. 2016 Dec 26. doi: 10.1002/ana.24853.
     PubMed    
     
     
     July 2016
143. WHITE MK, Wollebo HS, Beckham JD, Tyler KL, et al
     Zika virus: An emergent neuropathological agent.
     Ann Neurol. 2016 Jul 27. doi: 10.1002/ana.24748.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: